Hydroxyprogesterone acetate
| Clinical data | |
|---|---|
| Trade names | Prodrox | 
| Other names | OHPA; 17α-Hydroxyprogesterone acetate; 17α-Acetoxyprogesterone; Acetoxyprogesterone; 17α-Hydroxypregn-4-ene-3,20-dione 17α-acetate; 17α-Acetoxypregn-4-ene-3,20-dione | 
| Routes of administration | By mouth | 
| Drug class | Progestogen; Progestin; Progestogen ester | 
| ATC code | |
| Identifiers | |
| 
 | |
| CAS Number | 
 | 
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.005.564 | 
| Chemical and physical data | |
| Formula | C23H32O4 | 
| Molar mass | 372.505 g·mol−1 | 
| 3D model (JSmol) | |
| 
 | |
| 
 | |
Hydroxyprogesterone acetate (OHPA), sold under the brand name Prodox, is an orally active progestin related to hydroxyprogesterone caproate (OHPC) which has been used in clinical and veterinary medicine. It has reportedly also been used in birth control pills.
OHPA is a progestin, or a synthetic progestogen, and hence is an agonist of the progesterone receptor, the biological target of progestogens like progesterone.
OHPA was discovered in 1953 and was introduced for medical use in 1956.